The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Galena Biopharma Inc

Nasdaq: GALE
Last

(U.S.) $1.56

Today's change+0.06 +4.25%
Updated August 31 2:11 PM -4GMT. Delayed by at least 15 minutes.
 

Galena Biopharma Inc

Nasdaq: GALE
Last

(U.S.) $1.56

Today's change+0.06 +4.25%
Updated August 31 2:11 PM -4GMT. Delayed by at least 15 minutes.

Galena Biopharma Inc crosses above 20-day moving average

Galena Biopharma Inc is up sharply today, rallying (U.S.)$0.06 or 4.25% to (U.S.)$1.56 and crossing above its 20-day moving average. Over the last five days, shares have gained 4.25% and 3.56% year to date. Shares have underperformed the S&P 500 by 32.24% during the last year.

Key company metrics

  • Open(U.S.) $1.50
  • Previous close(U.S.) $1.50
  • High(U.S.) $1.59
  • Low(U.S.) $1.50
  • Bid / Ask(U.S.) $1.56 / (U.S.) $1.57
  • YTD % change+3.56%
  • Volume1,022,056
  • Average volume (10-day)1,839,183
  • Average volume (1-month)1,573,757
  • Average volume (3-month)2,747,085
  • 52-week range(U.S.) $1.10 to (U.S.) $2.50
  • Beta1.12
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.29
Updated August 31 2:11 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-368.37%

Galena Biopharma Inc has a net profit margin of -368.37%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.58%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue3332
Total other revenue--------
Total revenue3332
Gross profit3231
Total cost of revenue0000
Total operating expense15141414
Selling / general / administrative6787
Research & development7667
Depreciation / amortization0000
Interest expense (income), net operating--------
Unusual expense (income)000-1
Other operating expenses, total--------
Operating income-11-11-11-13
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-16-11-8-6
Income after tax-16-11-8-6
Income tax, total----00
Net income-16-11-8-6
Total adjustments to net income--------
Net income before extra. items-16-11-8-6
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-16-11-8-6
Inc. avail. to common incl. extra. items-16-11-8-6
Diluted net income-16-11-8-6
Dilution adjustment00--0
Diluted weighted average shares161136124119
Diluted EPS excluding extraordinary itemsvalue per share-0.10-0.08-0.06-0.05
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-0.10-0.08-0.07-0.06